Shanghai Best-Link Bioscience Overview
- Year Founded
-
2021
- Status
-
Private
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$58.7M
- Investors
-
9
Shanghai Best-Link Bioscience General Information
Description
Developer of biotechnology innovations designed to advance drug discovery and create novel therapeutics for oncology. The company offers proprietary discovery pipelines, nanomedicine expertise, and integrated preclinical development capabilities, enabling pharmaceutical partners and cancer patients access to targeted therapies with greater precision and clinical benefit.
Contact Information
Website
bestlinkbio.comCorporate Office
- 2nd and 3rd floors of Building 1
- Number 1299 Zhangheng Road
- Shanghai, Pudong 201203
- China
Corporate Office
- 2nd and 3rd floors of Building 1
- Number 1299 Zhangheng Road
- Shanghai, Pudong 201203
- China
Shanghai Best-Link Bioscience Timeline
Shanghai Best-Link Bioscience Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series C) | 15-May-2026 | $58.7M | Completed | Generating Revenue | ||
| 2. Early Stage VC (Series B) | 29-Dec-2025 | Completed | Generating Revenue | |||
| 1. Early Stage VC (Series A) | 04-Apr-2023 | $29M | $29M | Completed | Generating Revenue |
Shanghai Best-Link Bioscience Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Shanghai Best-Link Bioscience Patents
Shanghai Best-Link Bioscience Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026189356-A1 | Fulvestrant polylysine conjugate | Pending | 10-Mar-2025 | ||
| WO-2025242084-A1 | Lipid-drug conjugate as well as preparation therefor and use thereof | Pending | 20-May-2024 | ||
| WO-2025242083-A1 | Novel lipid nanodelivery material, preparation therefore and use thereof | Pending | 20-May-2024 | ||
| EP-4786521-A1 | Phospholipid drug conjugate, and preparation method and use therefor | Pending | 27-Sep-2023 | ||
| WO-2025067481-A1 | Phospholipid drug conjugate, and preparation method and use therefor | Inactive | 27-Sep-2023 | A61P35/00 |
Shanghai Best-Link Bioscience Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Junshi Biosciences | Corporation | Minority | ||
| CAS Star | Venture Capital | Minority | ||
| Hangzhou Hongcheng Capital | Growth/Expansion | Minority | ||
| SUNNOVO | Corporation | Minority | ||
| Teda VC | Venture Capital | Minority |
Shanghai Best-Link Bioscience FAQs
-
When was Shanghai Best-Link Bioscience founded?
Shanghai Best-Link Bioscience was founded in 2021.
-
Where is Shanghai Best-Link Bioscience headquartered?
Shanghai Best-Link Bioscience is headquartered in Shanghai, China.
-
What industry is Shanghai Best-Link Bioscience in?
Shanghai Best-Link Bioscience’s primary industry is Drug Discovery.
-
Is Shanghai Best-Link Bioscience a private or public company?
Shanghai Best-Link Bioscience is a Private company.
-
What is Shanghai Best-Link Bioscience’s current revenue?
The current revenue for Shanghai Best-Link Bioscience is .
-
How much funding has Shanghai Best-Link Bioscience raised over time?
Shanghai Best-Link Bioscience has raised $124M.
-
Who are Shanghai Best-Link Bioscience’s investors?
Junshi Biosciences, CAS Star, Hangzhou Hongcheng Capital, SUNNOVO, and Teda VC are 5 of 9 investors who have invested in Shanghai Best-Link Bioscience.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
